Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PACIFIC: Patient-reported outcomes unaffected by PD-L1 expression

Key clinical point: Level of programmed death-ligand 1 (PD-L1) expression does not impact self-reported outcomes of patients receiving durvalumab for stage III non–small cell lung cancer (NSCLC).

Major finding: Patients across five PD-L1 expression levels (at least 25%, less than 25%, at least 1%, less than 1%, and unknown) reported clinically relevant improvements in alopecia from baseline to week 48.

Study details: A retrospective analysis of patient-reported outcomes from the phase III PACIFIC trial, based on PD-L1 expression.

Disclosures: The study was funded by AstraZeneca. The investigators reported financial relationships with Roche, BMS, Lilly, and others.

Citation:

Garassino et al. ELCC 2019. Abstract LBA2.